| Ali Kheirbek, MD | |
|
90 W 86th Ave, Merrillville, IN 46410-7086 | |
| (219) 791-1555 | |
| (219) 791-4077 |
| Full Name | Ali Kheirbek |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 52 Years |
| Location | 90 W 86th Ave, Merrillville, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174520415 | NPI | - | NPPES |
| 100166520D | Medicaid | IN | |
| 090001077 | Other | IL | BCBS IDENTIFICATION NUMBE |
| 000000332607 | Other | IN | ANTHEM BCBS NUMBER |
| 100082060 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 01030716A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc - Neomedica - Munster | Munster, IN | Dialysis facility |
| Hammond Dialysis Center | Hammond, IN | Dialysis facility |
| Community Hospital | Munster, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology Associates Of Northern Indiana Pc | 8921033440 | 73 |
News Archive
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.
Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital infections and medical device failures.
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.
› Verified 2 days ago
| Entity Name | Nephrology Associates Of Northern Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578505814 PECOS PAC ID: 8921033440 Enrollment ID: O20051003000799 |
News Archive
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.
Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital infections and medical device failures.
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.
› Verified 2 days ago
| Entity Name | Nephrology Associates Of Northern Illinois Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124069182 PECOS PAC ID: 2163328675 Enrollment ID: O20170705000259 |
News Archive
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.
Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital infections and medical device failures.
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ali Kheirbek, MD 120 W 22nd St Ste 200, Oak Brook, IL 60523-1563 Ph: (630) 573-5000 | Ali Kheirbek, MD 90 W 86th Ave, Merrillville, IN 46410-7086 Ph: (219) 791-1555 |
News Archive
Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation.
A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.
Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital infections and medical device failures.
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy.
› Verified 2 days ago
Dr. Mihas Mamu Kodenchery, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 5800 Broadway, Suite A-j, Merrillville, IN 46410 Phone: 219-884-9185 | |
Omar Al Dhaybi, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 90 W 86th Ave, Merrillville, IN 46410 Phone: 219-791-1555 | |
Virginia Tan Tabib, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 8127 Merrillville Rd, Merrillville, IN 46410 Phone: 219-769-4855 Fax: 219-757-5629 | |
Dr. Mohammed Asgar, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 5490 Broadway Ste 106, Merrillville, IN 46410 Phone: 219-939-7130 Fax: 219-951-0883 | |
Gaurav Agarwal, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6061 Broadway, Merrillville, IN 46410 Phone: 219-884-2640 Fax: 219-884-2810 | |
Larry R Brazley, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 255 E 90th Dr, W1, Merrillville, IN 46410 Phone: 219-791-0248 Fax: 219-791-0251 | |
Stephanie D Marshall, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 8684 Connecticut St Ste A, Merrillville, IN 46410 Phone: 192-472-8990 Fax: 219-472-0270 |